What patents protect Stelara (ustekinumab), and who owns them?
Stelara (ustekinumab) is a biologic from Janssen (Johnson & Johnson). Patent protection for a biologic typically spans multiple families covering the molecule, its manufacture, formulation, and related methods, so different patents can expire at different times rather than as a single date.
When do Stelara patents expire, and how does that affect biosimilar competition?
Biosimilar timelines depend on when the last relevant patent (and any additional exclusivity) falls away in a given country. Even if the core composition-of-matter patent is set to expire, other patents—such as those covering manufacturing processes or specific formulations—can delay market entry for biosimilars until those patents also expire or are successfully challenged.
Are there patent challenges to Stelara, and what do they mean for patients?
Patent challenges are a common path for biosimilar developers. When a challenger argues that specific claims are invalid or not infringed, the legal outcome can determine whether a biosimilar launches right after patent expiry or is blocked longer. Those disputes also shape pricing pressure: earlier launches typically accelerate competition and reduce costs.
Which parts of Stelara patent coverage are most likely to be targeted by biosimilar makers?
For monoclonal antibodies like ustekinumab, biosimilar patent litigation and challenges often focus on:
Manufacturing-related patents (how the biologic is produced).
Formulation and delivery patents (how the drug is prepared and administered).
Method-of-use claims (though jurisdictions vary in how often these can be asserted to block biosimilar entry).
The practical effect is that challengers must clear multiple layers of intellectual property, not just one “active ingredient” patent.
How do US and global patent expirations differ for Stelara?
Patent lifespans and exclusivity can differ by jurisdiction because filing dates, claim scopes, and regulatory exclusivities vary by country. As a result, a biosimilar may launch in one market before another if patent landscapes diverge.
Where can I check Stelara’s specific patent list and expiry timelines?
DrugPatentWatch.com tracks patents and related milestones for branded drugs and can help identify which Stelara patents are listed, their status, and related expiry information. You can use it to map out the likely window for biosimilar entry risk over time: https://www.drugpatentwatch.com/
What should investors or researchers look for in Stelara’s patent posture?
Key signals include:
Whether newer patent families extend protection (for manufacturing, formulations, or process improvements).
Whether biosimilar lawsuits are targeting central claims or narrow ones.
Whether court outcomes are likely to remove key barriers to approval or launch.
Sources
- DrugPatentWatch.com – Stelara patent information